Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nurix Therapeutics (NRIX) EBT (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed EBT for 8 consecutive years, with -$87.2 million as the latest value for Q1 2026.

  • Quarterly EBT fell 54.7% to -$87.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$294.5 million through Feb 2026, down 41.45% year-over-year, with the annual reading at -$263.7 million for FY2025, 36.42% down from the prior year.
  • EBT for Q1 2026 was -$87.2 million at Nurix Therapeutics, down from -$78.2 million in the prior quarter.
  • The five-year high for EBT was -$24.3 million in Q2 2023, with the low at -$87.2 million in Q1 2026.
  • Average EBT over 5 years is -$51.1 million, with a median of -$45.4 million recorded in 2022.
  • The sharpest move saw EBT soared 46.53% in 2023, then plummeted 83.12% in 2024.
  • Over 5 years, EBT stood at -$46.7 million in 2022, then rose by 10.19% to -$42.0 million in 2023, then crashed by 39.53% to -$58.5 million in 2024, then tumbled by 33.62% to -$78.2 million in 2025, then decreased by 11.45% to -$87.2 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at -$87.2 million, -$78.2 million, and -$86.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.